Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPSC-Exos for Stable Vitiligo
NCT06810869Phase 1Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Wannan Medical College
- Start
- Feb 2025
- Primary completion
- Nov 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GD-iExo-003 in Vitiligo (5 arms), sponsored by The Second Affiliated Hospital of Wannan Medical College. Primary endpoint: Adverse events as assessed by CTCAE at 24 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
GD-iExo-003
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06810869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810869.